

April 29, 2022

The National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

The Bombay Stock Exchange Ltd Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400 001

Dear Sirs.

Sub: Outcome of Board Meeting held on 29-04-2022.

--0--

This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended March 31, 2022 and have also decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. The Board has fixed, Thursday 12th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend.

The Meeting commenced at 5.15 p.m. and concluded at 10.55 p.m. today.

Besides, the Board also approved granting of Stock Options to the eligible employees of the Company for the year 2021-22, subject to approval by Members.

Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the following are attached.

- 1. Stand-alone and Consolidated Audited Financial Results for the quarter and the financial year ended March 31, 2022.
- 2. Auditors' Report on the Stand-alone Financial Results for the year ended March 31, 2022.
- 3. Auditors' Report on the Consolidated Financial Results for the year ended March 31, 2022.



Thyrocare Technologies Limited



Further we hereby declare that the statutory auditors have issued unmodified opinion on both the Stand-alone and Consolidated Financial Results.

Yours Faithfully,

For Thyrocare Technologies Limited,

Ramjee Dorai

Company Secretary and Compliance Officer

